Skip to main content

Anti-Rheumatic Rx

Dr. John Cush @RheumNow( View Tweet )

Pragmatism in Gout: How therapeutic choices can have multiple benefits Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ
Dr. John Cush @RheumNow( View Tweet )
Retrospective study of 2187 RA pts initiating menopausal hormone Tx (MHT) vs 8,205 unexposed controls. VTE incidence higher among MHT users (6.49 vs 3.3/1000PY). MHT use was associated with a 92% signif increased risk of VTE in RA (adj HR: 1.92), mostly DVT risk (aHR: 2.26)

Dr. John Cush @RheumNow( View Tweet )

Genetic Risk Loci in Fibromyalgia

Researchers examined genetic data drawn from 11 different worldwide cohorts, that included from more than 2.5 million adults, of which 55,000 had been diagnosed with fibromyalgia. They identified DNA sequence variants in 26 regions of the genome that affect the risk of developing fibromyalgia.

Read Article

Uricase-Targeted Therapies in Gout

In most mammals, uricase catalyzes the oxidation of uric acid to allantoin, a highly soluble compound easily excreted by the kidneys. But humans lack functional uricase, leaving xanthine oxidase inhibitors (allopurinol/febuxostat) as first-line urate-lowering therapy (ULT). Uricase-based

Read Article

The Wider Implications of Dactylitis

Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA), but as Possemato and colleagues point out, it is fundamentally a clinical sign, and not a diagnosis. This review article discusses the wider implications of dactylitis in rheumatology and medicine underscores the

Read Article
UTSW observational study of labs (n 14,199) changes w/ MTX use in 2,439 pts (13% RA, 11% PsO/PsA, 15% inflam arthritis) - found no difference in labs q3 vs q6 mos. No signif correlation betw monitoring intervals & changes in ALT, AST,WBC, HCT, MCV, PLT, FIB-4. Small https://t.co/gKwA7juexG
Dr. John Cush @RheumNow( View Tweet )

When Gout Flares, So Does the Cardiovascular System

We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title says it well — gout is more than flares. I would add

Read Article
Expert Perspective on Calcium Pyrophosphate Deposition Disease A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl
Dr. John Cush @RheumNow( View Tweet )
Pragmatism in Gout: How therapeutic choices can have multiple benefits William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. https://t.co/DG29pro6XE
Dr. John Cush @RheumNow( View Tweet )

Chikungunya Club Meeting (7.24.2026)

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.

Read Article

Swimming Reduces Disability from Low Back Pain

EurekAlert!

Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically effective in reducing disability from chronic low back pain

Read Article
EUSTAR scleroderma substudy propensity matched pts Rx w/ JAKi (n 38) vs 180 pts ea Rx w/ MMF, MTX, RTX. 1/3 had dcSSc. 23 AEs in 997 Pt-yrs. JAKi outcomes similar to comparators. JAKi Tx D/C in 39%, FVC stable, skin fibrosis improved (mRSS −1.8) & SJC decreased. No new

Dr. John Cush @RheumNow( View Tweet )

The Lancet Rheumatology has a good editorial about the avacopan bad news reports with EMA, FDA and Japan issuing negative opinions that threaten the drugs future. Yet, since approval real world data on avacopan has been favorable w/ less steroid toxicity & most hepatotoxicity https://t.co/k6ebVeWv2K
Dr. John Cush @RheumNow( View Tweet )

Interferon-α as an Immunologic Driver of Sjögren's Disease

Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and
Read Article
Allopurinol - severe allergic reactions are estimated at 0.4%-2%, rising to 8–18% in patients with chronic kidney disease. Being HLA-B*58:01 (+) dramatically increases risk (OR 117). For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/fTuc4lYvJz
Dr. John Cush @RheumNow( View Tweet )
Psoriatic Arthritis: EULAR 2026 Recap https://t.co/tBMu4CEn0o https://t.co/iztShOHxOf
Dr. John Cush @RheumNow( View Tweet )
Gout master class @RheumNow Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) https://t.co/yvSkULQlyR via @YouTube

Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )

2 Still's dz cohorts (96 Shanghai, 28 Erlangen0 compared response to biolgics vs DMARDs (MTX, CNI,JAKi). in 124 AOSD pts, biologic had more sustained event-free remission and event-free state (P 0.0065, P 0.0096) & more steroid D/C vs MTX/CNI (p < 0.05). https://t.co/lJaI9nhPYr

Dr. John Cush @RheumNow( View Tweet )

From 2015-2024, 148 inflam arthritis pts (43 SpA, 35 PsA, 50 RA) w/ a prior cancer were followed 58.1 mos. 24 (19%) had CA recurrence/progression. Post-CA exposure to b/ts-DMARDs did not incr. recurrence risk after adjusting for age & comorbidity burden. https://t.co/MHKIqwyjNN https://t.co/uhOdq1cCPW
Dr. John Cush @RheumNow( View Tweet )
RHEUM SURVEY Q: Which gout drug has the greatest toxicity risk? Answer here>> https://t.co/EQrEjD9237

Dr. John Cush @RheumNow( View Tweet )

SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg
Dr. John Cush @RheumNow( View Tweet )

Expert Perspective on Calcium Pyrophosphate Deposition Disease

A recent perspective by Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments.

Read Article

Pragmatism in Gout: How therapeutic choices can have multiple benefits

William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in

Read Article
Tomorrow! Registration is still open! Time-tested gout therapies remain the cornerstone of care, optimizing their use requires thoughtful, patient-specific decision making. Join our expert faculty for Upgrading & Maximizing the Classics where they'll explore practical https://t.co/ZN0vcVjUex
Dr. John Cush @RheumNow( View Tweet )
×